Although there are many treatment methods for proteinuria in renal transplanted patients, none have been found to be definitively effective.
We examined the clinical effects of the administration of Sairei-to on 11 renal transplanted patients with proteinuria. Clinical evaluation was carried out over six months of administration. The patients were divided into the chronic rejection group, consisting of four patients, and the non-chronic rejection group. Although no improvement was seen in the chronic rejection group, three out of seven patients in the non-chronic rejection group showed improvement in proteinuria, and one exhibited improved kidney function. In one of the improved proteinuria cases, a reduction in nephrotoxicity of the immunosuppressor FK506 was suggested.
According to these results, Sairei-to may be effective in the treatment of proteinuria in renal transplanted patients without chronic rejection.